Theoretically, BPC-157 shows faster onset (4-6 days in animal models vs 2-6 weeks for human SSRIs), multi-system modulation rather than single-target effects, actual neuronal repair and regeneration (neuroprotection), no withdrawal syndrome in animals, and efficacy when given peripherally without extensive blood-brain barrier crossing
The peptides chelation of copper prevents oxidative damage while enabling controlled cellular uptake, distinguishing it from other copper delivery methods
Perhaps most significantly, not a single serious adverse event was attributed to AOD-9604 administration across the entire trial program
Certificate of Analysis available) Form : Sterile, lyophilized white powder for reconstitution Sequence Confirmation : BPC-157 GEPPPGKPADDAGLV
(2) D Gwyer, N M Wragg, and S L Wilson (2019)